Literatur
- 1 Jahresbericht 2005 des Deutschen Kinderkrebsregisters. Mainz; Institut für Medizinische
Statistik und Dokumentation, Universität Mainz, Germany 2006
- 2
Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh J W, Lacour B. et
al .
Geographical patterns and time trends of cancer incidence and survival among children
and adolescents in Europe since the 1970s (the ACCIS project): an epidemiological
study.
Lancet.
2004;
364
2097-2105
- 3
Pui C H, Evans W E.
Acute lymphoblastic leukemia.
N Engl J Med.
1998;
339
605-615
- 4
Bennett J M, Catovski D, Daniel M T, Flandrin G, Galton D AG, Gralnick H R. et al
.
Proposals for the classification of the acute leukaemias. French-American-British
(FAB) cooperative group.
Br J Haematol.
1976;
33
451-458
- 5
Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R. et al .
Proposed revised criteria for the classification of acute myeloid leukemia. A report
of the French-American-British Cooperative Group.
Ann Intern Med.
1985;
103
620-625
- 6
Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R. et al .
Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report
of the French-American-British Cooperative Group.
Ann Intern Med.
1985;
103
460-462
- 7
Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R. et al .
Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO).
Br J Haematol.
1991;
78
325-329
- 8
Ritter J, Gaedicke G, Winkler K, Beckmann H, Landbeck G.
Letter: Possible T-cell origin of lymphoblasts in acid-phosphatase-positive acute
lymphatic leukaemia.
Lancet.
1975;
2
75
- 9
Bene M C, Castoldi G, Knapp W, Ludwig W D, Matutes E, Orfao A. et al .
Proposals for the immunological classification of acute leukemias. European Group
for the Immunological Characterization of Leukemias (EGIL).
Leukemia.
1995;
9
1783-1786
- 10
Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M. et al .
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden
and improve survival: treatment results of 2169 unselected pediatric and adolescent
patients enrolled in the trial ALL-BFM 95.
Blood.
2008;
111 (9)
4477-4489
- 11
Yeoh E J, Ross M E, Shurtleff S A, Williams W K, Patel D, Mahfouz R. et al .
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic
leukemia by gene expression profiling.
Cancer Cell.
2002;
1
133-43
- 12
Greaves M F, Colman S M, Beard M E, Bradstock K, Cabrera M E, Chen P M. et al .
Geographical distribution of acute lymphoblastic leukaemia subtypes: second report
of the collaborative group study.
Leukemia.
1993;
7
27-34
- 13 Mahony D.
Acute lymphoblastic leukemia. In: McMillan JA, Deangelis CD, Feigin RD, Warshaw JB, eds Oski’s pediatrics. Philadelphia;
Lippinscott, Williams and Wilkins 1999: 1493-1501
- 14
Ford A M, Ridge S A, Cabrera M E, Mahmoud H, Steel C M, Chan L C. et al .
In utero rearrangements in the trithorax-related oncogene in infant leukaemias.
Nature.
1993;
363
358-360
- 15
Wiemels J L, Ford A M, van Wering E R, Postma A, Greaves M.
Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene
fusion in utero.
Blood.
1999;
94
1057-1062
- 16
Gale K B, Ford A M, Repp R, Borkhardt A, Keller C, Eden O B. et al .
Backtracking leukemia to birth: identification of clonotypic gene fusion sequences
in neonatal blood spots.
Proc Natl Acad Sci USA.
1997;
94
13 950-13 954
- 17
Wiemels J L, Cazzaniga G, Daniotti M, Eden O B, Addison G M, Masera G. et al .
Prenatal origin of acute lymphoblastic leukaemia in children [see comments].
Lancet.
1999;
354
1499-1503
- 18
Fasching K, Panzer S, Haas O A, Marschalek R, Gadner H, Panzer-Grumayer E R.
Presence of clone-specific antigen receptor gene rearrangements at birth indicates
an in utero origin of diverse types of early childhood acute lymphoblastic leukemia.
Blood.
2000;
95
2722-2724
- 19
Greaves M.
Childhood leukaemia.
Bmj.
2002;
324
283-287
- 20
Hoshino T.
Symposium: Epidemiology of leukemia in Japan. Etiologic role of ionizing radiation
on the development of leukemia: clinical and statistical studies on leukemia in patients
treated with radioiodine and in atomic bomb surviviors.
Nippon Ketsueki Gakkai Zasshi.
1968;
31
825-831
- 21
Hayes R B, Songnian Y, Dosemeci M, Linet M.
Benzene and lymphohematopoietic malignancies in humans.
Am J Ind Med.
2001;
40
117-126
- 22
Adamson R H, Seiber S M.
Chemically induced leukemia in humans.
Environ Health Perspect.
1981;
39
93-103
- 23 Nerurkar L S.
Human retroviruses, leukemia and AIDS. In: Henderson ES, Lister TA, eds Leukemia. London; W. B. Saunders Company 1991: 228-229
- 24
Alexander F E, Daniel C P, Armstrong A A, Clark D A, Onions D E, Cartwright R A. et
al .
Case clustering, Epstein-Barr virus Reed-Sternberg cell status and herpes virus serology
in Hodgkin’s disease: results of a case-control study.
Eur J Cancer.
1995;
31A
1479-1486
- 25
Jarrett R F.
Viruses and lymphoma/leukaemia.
J Pathol.
2006;
208
76-186
- 26
MacKenzie J, Gallagher A, Clayton R A, Perry J, Eden O B, Ford A M. et al .
Screening for herpesvirus genomes in common acute lymphoblastic leukemia.
Leukemia.
2001;
15
415-421
- 27
Greaves M.
Infection, immune responses and the aetiology of childhood leukaemia.
Nat Rev Cancer.
2006;
6
193-203
- 28
Heath Jr. C W, Hasterlik R J.
Leukemia among children in a suburban community. 1963.
CA Cancer J Clin.
1990;
40
27-50
- 29
McNally R J, Eden T O.
An infectious aetiology for childhood acute leukaemia: a review of the evidence.
Br J Haematol.
2004;
127
243-263
- 30
Istre G R, Conner J S, Broome C V, Hightower A, Hopkins R S.
Risk factors for primary invasive Haemophilus influenzae disease: increased risk from
day care attendance and school-aged household members.
J Pediatr.
1985;
106
190-195
- 31
Greaves M F.
Aetiology of acute leukaemia.
Lancet.
1997;
349
344-349
- 32
Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H. et al .
Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic
leukemia in childhood: significantly lower risk without cranial radiotherapy.
Blood.
2000;
95
2770-2775
- 33
Haase D, Feuring-Buske M, Konemann S, Fonatsch C, Troff C, Verbeek W. et al .
Evidence for malignant transformation in acute myeloid leukemia at the level of early
hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations.
Blood.
1995;
86
2906-2912
- 34
Fenaux P.
Results of APL 91 European trial combining ATRA and chemotherapy: presentation of
APL 1993 trial.
Leukemia.
1994;
8 (Suppl. 3)
S70-S72
- 35
Fenaux P.
Treatment of newly diagnosed APL. The best choice is not ATRA or chemotherapy ...
but a combination of both. European APL Group.
Leukemia.
1994;
8 (Suppl. 2)
S59-S61
- 36
Fenaux P, Chastang C, Degos L.
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of
all-trans retinoic acid (ATRA) and chemotherapy. French APL Group.
Leukemia.
1994;
8 (Suppl. 2)
S42-S47
- 37
Gregory J, Arceci R.
Acute myeloid leukemia in children: a review of risk factors and recent trials.
Cancer Invest.
2002;
20
1027-1037
- 38
Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Loffler H. et al .
Definition of a standard-risk group in children with AML.
Br J Haematol.
1999;
104
630-639
- 39
Creutzig U, Ritter J, Vormoor J, Eschenbach C, Dickerhoff R, Burdach S. et al .
[Transient myeloproliferation and acute myeloid leukemia in infants with Down’s syndrome].
Klin Padiatr.
1990;
202
253-257
- 40
Ravindranath Y, Abella E, Krischer J P, Wiley J, Inoue S, Harris M. et al .
Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy:
experience on Pediatric Oncology Group AML Study 8498.
Blood.
1992;
80
2210-2214
- 41
Lie S O, Jonmundsson G, Mellander L, Siimes M A, Yssing M, Gustafsson G.
A population-based study of 272 children with acute myeloid leukaemia treated on two
consecutive protocols with different intensity: best outcome in girls, infants, and
children with Down’s syndrome. Nordic Society of Paediatric Haematology and Oncology
(NOPHO).
Br J Haematol.
1996;
94
82-88
- 42
Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M.
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced
dose intensity.
Leukemia.
2005;
19
1355-1360
- 43
Ravindranath Y.
Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia
and heightened sensitivity to chemotherapy.
J Clin Oncol.
2003;
21
3385-3387
- 44
Abildgaard L, Ellebaek E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G. et al
.
Optimal treatment intensity in children with Down syndrome and myeloid leukaemia:
data from 56 children treated on NOPHO-AML protocols and a review of the literature.
Ann Hematol.
2006;
85
275-280
- 45
Tefferi A.
Chronic myeloid disorders: Classification and treatment overview.
Semin Hematol.
2001;
38(Suppl. 2)
1-4
- 46
Garre M L, Gandus S, Cesana B, Haupt R, De Bernardi B, Comelli A. et al .
Health status of long-term survivors after cancer in childhood. Results of an uniinstitutional
study in Italy.
Am J Pediatr Hematol Oncol.
1994;
16
143-152
- 47
Lackner H, Benesch M, Schagerl S, Kerbl R, Schwinger W, Urban C.
Prospective evaluation of late effects after childhood cancer therapy with a follow-up
over 9 years.
Eur J Pediatr.
2000;
159
750-758
- 48
Oeffinger K C, Eshelman D A, Tomlinson G E, Buchanan G R, Foster B M.
Grading of late effects in young adult survivors of childhood cancer followed in an
ambulatory adult setting.
Cancer.
2000;
88
1687-1695
- 49
Pemberger S, Jagsch R, Frey E, Felder-Puig R, Gadner H, Kryspin-Exner I. et al .
Quality of life in long-term childhood cancer survivors and the relation of late effects
and subjective well-being.
Support Care Cancer.
2005;
13
49-56
- 50
Stevens M C, Mahler H, Parkes S.
The health status of adult survivors of cancer in childhood.
Eur J Cancer.
1998;
34
694-698
- 51
Hertzberg H, Huk W J, Ueberall M A, Langer T, Meier W, Dopfer R. et al .
CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings
in long-term survivors of childhood ALL – An evaluation of the interferences between
morphology and neuropsychological performance.
Med Pediatr Oncol.
1997;
28
387-400
- 52
Brown R T, Madan-Swain A, Lambert R.
Posttraumatic stress symptoms in adolescent survivors of childhood cancer and their
mothers.
J Trauma Stress.
2003;
16
309-318
- 53
Langeveld N E, Ubbink M C, Last B F, Grootenhuis M A, Voute P A, de Haan R J.
Educational achievement, employment and living situation in long-term young adult
survivors of childhood cancer in the Netherlands.
Psychooncology.
2003;
12
213-225
- 54
Calaminus G, Langer T, Willich N, Beck J D.
Lebensqualität und Spätfolgen bei Kindern und Jugendlichen mit Krebserkrankungen.
Onkologe.
2000;
6
868-877
- 55
Langer T, Henze G, Beck J D.
Basic methods and the developing structure of a late effects surveillance system (LESS)
in the long-term follow-up of pediatric cancer patients in Germany. For the German
Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH).
Med Pediatr Oncol.
2000;
34
348-351
- 56
Boman K K, Bodegard G.
Life after cancer in childhood: social adjustment and educational and vocational status
of young-adult survivors.
J Pediatr Hematol Oncol.
2004;
26
354-362
- 57
Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A. et al .
Varicella vaccination in a child with acute lymphoblastic leukaemia.
Lancet.
2007;
369
1232
PD Dr. med. Melchior Lauten
Zentrum für Kinder- und JugendmedizinUniversitätsklinikum Freiburg
Mathildenstr. 12
70106 Freiburg
Fax: 0761-270 4918
Email: melchior.lauten@uniklink-freiburg.de
